Clinical analysis of 36 multiple myeloma patients with extramedullary plasmacytoma invasion of the spinal canal

Hematological Oncology

Volumn 33, Issue 2, 2015, Pages 75-79

  Zhang, Jiajia ^a   Zhong, Yuping ^a,b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bortezomib; Multiple myeloma; Spinal canal invasion

Indexed keywords

BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE; VINDESINE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PARAPROTEIN; PYRAZINE DERIVATIVE;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL INFILTRATION; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; ELECTROPHORESIS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INFECTION; LIMB WEAKNESS; LOW BACK PAIN; LUMBAR SPINAL CORD; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARESTHESIA; PERIPHERAL NEUROPATHY; PLASMACYTOMA; PRIORITY JOURNAL; SACRAL SPINAL CORD; SOFT TISSUE TUMOR; SPINE METASTASIS; SURVIVAL RATE; THORACIC SPINAL CORD; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR INVASION; VERTEBRAL CANAL; BONE MARROW; COMPLICATION; DECOMPRESSION SURGERY; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SPINAL CORD COMPRESSION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; BORONIC ACIDS; BORTEZOMIB; COMBINED MODALITY THERAPY; DECOMPRESSION, SURGICAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYELOMA PROTEINS; NEOPLASM INVASIVENESS; PROGNOSIS; PYRAZINES; RETROSPECTIVE STUDIES; SPINAL CANAL; SPINAL CORD COMPRESSION; TREATMENT OUTCOME;

EID: 84930925927     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.2126     Document Type: Article

References (22)

1. Churg J, Gordon AJ. Multiple myeloma with unusual visceral involvement. Arch Pathol 1942; 34: 546-556.
2. Churg J, Gordon AJ. Multiple myeloma: lesions of the extra-osseous hematopoietic system. Am J Clin Pathol 1950; 20: 934-945.
3. Hayes DW, Bennett WA, Heck FJ. Extramedullarylesions in multiple myeloma: review of literature and pathologic studies. AMA Arch Pathol 1952; 53: 262-272.
4. Pasmantier MW, Azar HA. Extraskeletal spread in multiple plasma cell myeloma: a review of 57 autopsied cases. Cancer 1969; 23: 167-174.
5. Bladé J, Lust J, Kyle RA. Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases. J Clin Oncol 1994; 12: 2398-2404.
6. Bladé J, Kyle RA, Greipp PR. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol 1996; 93: 345-351.
7. Wu P, Davies F, Boyd K, et al. The impact of extramedullary disease at presentation in the outcome of myeloma. Leuk Lymphoma 2009; 50: 230-235.
8. Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1, 003 consecutive patients. Ann Oncol 2009; 21: 325-330.
9. Qu XY, Fu WJ, Xi H, Zhou F, Wei W, Hou J. Clinical features of multiple myeloma invasion of the central nervous system in Chinese patients. Chin Med J (Engl) 2010; 123: 1402-1406.
10. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757.
11. Dinse GE, Lagakos SW. Nonparametric estimation of lifetime and disease onset distributions from incomplete observations. Biometrics 1982; 38: 921-932.
12. Alexiou C, Kau RJ, Dietzfelbinger H, et al. Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Cancer 1999; 85: 2305-2314.
13. Feng PH, Huang CC, Wang CW, Wu YK, Tsai YH. Solitary pleural plasmacytomas manifested as a massive pleural effusion without evidence of monoclonal gammopathy. Respirology 2008; 13: 751-753.
14. Repko M, Chaloupka R, Grosman R, et al. Surgical options in the treatment of myeloma of the spine. Vnitr Lek 2006; 52(suppl12): 32-40.
15. Fassas AB, Ward S, Muwalla F, et al. Myeloma of the central nervous system: strong association with unfavorable chromosomal abnormalities and other high-risk disease features. Leuk Lymphoma 2004; 45: 291-300.
16. Blade J, Fernandez de Larrea C, Rosinol L, et al. Soft-tissue plasmacytomas in multiple myeloma: Incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol 2011; 29: 3850-3812.
17. Dimopoulos M, Terpos E, Comenzo RL, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple myeloma. Leukemia 2009; 23: 1545-1556.
18. Bartel TB, Haessler J, Brown TL, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood 2009; 114: 2068-2076.
19. van Rhee F, Bolejack V, Hollmig K, et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 2007; 110: 827-832.
20. Rosinol L, Cibeira MT, Martinez J, et al. Thalidomide/dexamethasone (TD) vs. bortezomib (Velcade)/Thalidomide/dexamethasone (VTD) vs. VBMCP/VBAD/Velcade as induction regimens prior autologous stem cell transplantation (ASCT) in multiple myeloma (MM): results of a phase III PETHEMA/GEM trial. Blood (ASH Annual Meeting Abstracts) 2009; 114: 130. Abstract.
21. Zhong YP, Chen SL, Li X, Hu Y, Zhang JJ. Bortezomib combined with other drugs for treating 60 cases of multiple myeloma. J Expert Hematol 2009; 1: 214-217.
22. Dytfeld D, Matuszak M, Lewandowski K, Komarnicki M. Bortezomib in combination with thalidomide and dexamethasone- a successful treatment regimen in refractory extramedullary multiple myeloma. Ann Hematol 2008; 87: 253-254.